MRSA drug dosage calculations found to be inaccurate for children over 10

The emergence of MRSA (Staphylococcus aureus), dubbed a 'superbug' due to its resistance to many antibiotic drugs, has resulted in the glycopeptide antibiotic Vancomycin being commonly prescribed for patients in hospital.

However, MRSA's resistance to drugs has led to concerns of a 'creeping minimum' in the concentration of the dosage required to treat infection. In , nomograms are used to calculate the correct dosage of Vancomycin based on a patient's weight and creatinine levels.

While these adult nomograms are widely thought to be suitable for teenagers, pharmacological differences between teens and young adults remain poorly understood.

New research, published in the Journal of Clinical Pharmacology, explores the accuracy of adult nomograms in children over ten. The results of 120 patients from a children's' hospital in Vanderbilt, Nashville, revealed that Vancomycin nomograms from adults were not accurate in predicting appropriate dosing levels in .

"Based on the variability of pharmacokinetic parameters and drug clearance, the two Vancomycin nomograms developed to predict therapeutic Vancomycin concentrations in healthy adults did not accurately estimate dosage regimens in older children regardless of weight or age, and therefore should not be used to aid empiric dosing," said Dr. Jessica Gillon. "Further prospective studies are warranted for teens between 10 and 18 years of age to determine the most appropriate Vancomycin dosing to maximize drug efficacy and reduce the risk of Vancomycin induced renal toxicity."

More information: Jessica E. Gillon, James E. Cassat, M. Cecilia Di Pentima, 'Validation of two vancomycin nomograms in patients 10 years of age and older' The Journal of Clinical Pharmacology, Wiley, DOI: 10.1002/jcph.173

add to favorites email to friend print save as pdf

Related Stories

Less commonly prescribed antibiotic may be better

Aug 16, 2012

The antibiotic most commonly prescribed to treat bloodstream infections in dialysis patients may not always be the best choice, according to a study appearing in an upcoming issue of the Journal of the American Society of ...

Vibativ approved for certain bacterial pneumonia

Jun 24, 2013

(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Recommended for you

FDA reconsiders behavior-modifying 'shock devices'

9 hours ago

(HealthDay)—They're likened to a dog's "shock collar" by some and called a "life-saving treatment" by others. But the days of electro-shock devices as a tool for managing hard-to-control behavior in people ...

FDA proposes accelerated medical device approval plan

Apr 23, 2014

(HealthDay)—The U.S. Food and Drug Administration has proposed a new program that would provide expedited access to high-risk medical devices intended for patients with serious conditions whose medical ...

Targeting drugs to reduce side effects

Apr 23, 2014

(Medical Xpress)—Consider ice cream – the base of which is frozen cream. Ingredients are then added to make different flavours. All these flavours are distinctly different but are created from the same foundation.

User comments